{
    "id": 8913,
    "fullName": "MUC16 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MUC16 over exp indicates an over expression of the Muc16 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 94025,
        "geneSymbol": "MUC16",
        "terms": [
            "MUC16",
            "CA125"
        ]
    },
    "variant": "over exp",
    "createDate": "07/10/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2519,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, treatment with Abagovomab as maintenance therapy did not improve overall survival or recurrence-free survival in patients with ovarian cancer (PMID: 23478059).",
            "molecularProfile": {
                "id": 8809,
                "profileName": "MUC16 over exp"
            },
            "therapy": {
                "id": 2892,
                "therapyName": "Abagovomab",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3208,
                    "pubMedId": 23478059,
                    "title": "Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23478059"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2520,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Oregovomab as consolidation therapy did not improve time-to-progression compared to placebo in patients with ovarian cancer (PMID: 15337799).",
            "molecularProfile": {
                "id": 8809,
                "profileName": "MUC16 over exp"
            },
            "therapy": {
                "id": 1189,
                "therapyName": "Oregovomab",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3220,
                    "pubMedId": 15337799,
                    "title": "Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15337799"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8809,
            "profileName": "MUC16 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 6010,
                    "name": "MUC16 Targeted Therapy",
                    "profileName": "MUC16 over exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}